Lilly Articles
AstraZeneca's 1st-qtr sales pass $5 billion
3 May 2004
Tokyo pharma stocks - week to April 26
3 May 2004
Bayer/GSK's Levitra takes 3rd place in UK
3 May 2004
Stock Commentary - New York
26 April 2004
Lilly sees sales climb 17% for 1st-qtr 2004
26 April 2004
Class action filed over Zyprexa side effects
26 April 2004
Hungarian govt goes ahead with 15% drug price reductions
19 April 2004
Global peripheral neuropathy market worth $1B by 2012
19 April 2004
Stock Commentary - New York
12 April 2004
Confusion in EU biogenerics sector
5 April 2004
Stock Commentary - New York
5 April 2004
FDA appro for Lilly's injectable Zyprexa
5 April 2004
FDA appro for Lilly's injectable Zyprexa
5 April 2004
Positive EU opinion for Lilly/BI's duloxetine
5 April 2004
Stock Commentary - New York
29 March 2004
AXM Pharma hires Hao Zhang as VP marketing
29 March 2004
Lilly's Cialis bites into Viagra's market share
29 March 2004
6M Americans have bought drugs on-line
29 March 2004
Thumbs-up for Viagra in ED treatment survey
29 March 2004
InnoCentive and NCL announce partnership
29 March 2004
Ranbaxy launches Forzest in India for ED
22 March 2004
Stock Commentary - New York
15 March 2004
Lilly to advance LY519818 into Ph III
8 March 2004
New data for Bayer/GSK's Levitra
8 March 2004
Healthy interim ressults for S Africa's Aspen
1 March 2004
Amylin reports 12% rise in 2003 net loss
1 March 2004
Lilly ICOS' Cialis gets EU label change
1 March 2004
Tokyo pharma stocks - week to Feb 23
1 March 2004
Lilly aids in center of excellence in protein sciences
23 February 2004
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
Lilly completes acquisition of Applied Molecular
23 February 2004
Stock Commentary - New York
16 February 2004
Eli Lilly tightens anticounterfeiting measures
16 February 2004
Lilly's Alimta cleared by FDA
16 February 2004
Stock Commentary - New York
9 February 2004
Injectable Zyprexa launched in UK by Lilly
9 February 2004
Dr Reddy's 3rd-qtr net profit falls 11%
9 February 2004
Strong 2003 sales for Lilly but profits flat
9 February 2004
Lilly ICOS Cialis sales exceed $200M
2 February 2004
Stock Commentary - New York
2 February 2004
Sirna and Lilly enter RNAi collaboration
2 February 2004
New US Cialis ad to debut at Super Bowl
2 February 2004
Cellular Genomics raises $22.3 million
2 February 2004
Lilly: first drug major for Medicare benefit?
26 January 2004
Generics "can be dearer in Canada than USA"
26 January 2004
US Congress moves on fake drugs, diversion
26 January 2004
UPDATE: Lilly's Zyprexa gets OK from FDA for new use
26 January 2004
Lilly's Zyprexa gets OK from FDA for new use
19 January 2004
Hydra completes $18.9M financing
19 January 2004
New Chemical Entities in 2003
19 January 2004
Lilly MedTech Venture Fund launched
19 January 2004
How pharma is tackling the issue of non-compliance; study
19 January 2004
Stock Commentary - New York
5 January 2004
Tokyo pharma stocks - week to Jan 5
5 January 2004
Aventis submits NDA for once-daily Alegra
5 January 2004
Lilly drug cleared for depressive bipolar disease
5 January 2004
Lilly and Takeda sign deal for ruboxistaurin
5 January 2004
Lilly acquisition of Applied Molecular passes H-S-R period
30 November 2003
Fortune names Lilly among best 100 to work for
30 November 2003
Pfizer warns Canadian pharmacies over exports
30 November 2003
"Self-correcting balance" between brand, generics firms, both using "creative" tactics
22 December 2003
Stock Commentary - New York
15 December 2003
Stock Commentary - New York
24 November 2003
GPC Biotech aiming to build broad oncology pipeline
24 November 2003
Shire beats expectations in third quarter as ADHD product sales soar
17 November 2003
Amersham sells screening technology to Eli Lilly
17 November 2003
Teva stays ahead of the pack with $3.4 billion Sicor acquisition
10 November 2003
Michael McDonal joins Seattle Genetics as chief medical officer
10 November 2003
Eli Lilly's Forsteo launched in EU
10 November 2003
Promising new results for Lilly's Xigris
10 November 2003
Stock Commentary - New York
3 November 2003
Tokyo pharma stocks - week to Sept 29
3 November 2003
Eli Lilly limits supplies to Canadian pharmacies
27 October 2003
Elections at India's OPPI
27 October 2003
Launches hit Lilly's profits, sales strong
27 October 2003
Impotence drugs selling fast in South Korea
27 October 2003
Eli Lilly's Strattera gains 16.3% of new Rxs in the USA
27 October 2003
PhRMA's "$8.5M lobby bill in 2003 to date"
20 October 2003
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
